Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone

Lindsay M. Mailloux, PharmD1; Matthew T. Haas, PharmD, BCPP, BCPS2; Janel M. Larew, PharmD, BCPS3; Beth M. DeJongh, PharmD, BCPP, BCPS4

How to cite: Mailloux LM, Haas MT, Larew JM, DeJongh BM. Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone. Ment Health Clin [Internet]. 2021;11(1):35-9. DOI: 10.9740/mhc.2021.01.035.

Abstract

Introduction: Physician-pharmacist collaborative practice models (PPCPM) decrease barriers and increase access to medications for opioid use disorder (MOUD) but are not routine in practice. The purpose of this quality improvement initiative is to develop and implement a PPCPM for management of patients on MOUD with buprenorphine/naloxone to minimize provider burden, expand access to treatment, and enhance overall patient care.

Methods: A PPCPM for management of patients on MOUD with buprenorphine/naloxone was piloted in an outpatient substance use disorder clinic. Approximately 4 hours per week were dedicated to physician-pharmacist collaborative medical appointments for a 5-month trial period. The pharmacist met with the patient first and then staffed the case with the collaborating psychiatrist. Descriptive data from PPCPM appointments was collected and compared to data from psychiatrist-only appointments.

Results: Twenty-five patients were seen over 44 appointments with an estimated 33 hours of psychiatrist time saved. Average initial and end buprenorphine doses, urine drug screen (UDS) results, and mental health (MH) medication interventions were similar between patients seen in PPCPM appointments compared with those seen in psychiatrist-only appointments. Collection of UDS, identification and management of MOUD adherence issues, other service referrals, and medication reconciliation intervention were more frequent in PPCPM appointments.

Discussion: Implementation of a PPCPM allowed for provision of a similar level of care regarding MOUD and MH-related medication management while saving psychiatrist time. Other enhancements to patient care provided through pharmacist intervention included more frequent identification and management of MOUD adherence issues, referral for other services, and medication reconciliation interventions.

Keywords: opioid use disorder, opioid dependence, collaborative practice model, buprenorphine/naloxone, medications for opioid use disorder, pharmacist

Disclosures: There are no actual or potential conflicts of interest by any authors of this article.

Introduction

In 2018, 2 million people in the United States were estimated to have an OUD.1 Opioid-related drug overdose accounted for 70% (46,802) of drug overdose deaths in 2018.2
Despite benefits of buprenorphine treatment, patient access to services is limited due to an overall shortage of psychiatrists and underutilization by prescribers. Providers with the credentialing to prescribe buprenorphine consistently prescribe below their capacity. A study specific to the Veterans Health Administration (VHA) shows that 43% of the credentialed providers had not prescribed any buprenorphine in the preceding 180 days. Those who prescribed at least 1 prescription only prescribed at 18.5% of their patient panel capacity on average. Physician-reported barriers to prescribing buprenorphine include insufficient support, demands of the induction period, insufficient time or space in the current practice, stigma, and lack of interest or education.

Physician-pharmacist collaborative practice models (PPCPM) help decrease these barriers, increase access to treatment, and retain patients in treatment programs. Pharmacists must take a collaborative role to support X-waiver providers because they are not currently eligible for X-waiver certification. After review of the literature, it appears that programs integrating pharmacists into MOUD services are not routine in practice, and literature showing specific benefits added to patient care provided by pharmacists is lacking. The purpose of this quality improvement initiative was to develop and implement a PPCPM for management of patients with OUD on buprenorphine/naloxone to minimize provider burden, expand access to treatment, and enhance overall patient care.

Methods

A PPCPM for management of patients with OUD on buprenorphine/naloxone was piloted at the Clement J. Zablocki Veterans Affairs Medical Center outpatient SUD clinic. The collaborating physician was a board-certified psychiatrist with a fellowship in addiction psychiatry. The pharmacist was completing a PGY-2 residency in psychiatric pharmacy, had a scope of practice in MH, and completed the Drug Addiction Treatment Act of 2000 X-waiver training.

The pilot project was trialed from October 18, 2019, to March 6, 2020. Approximately 4 hours per week was dedicated to PPCPM appointments. Patients were included if they were being treated with buprenorphine/naloxone under the care of the addiction psychiatrist and had appointments scheduled during the allotted clinic time. The pharmacist saw the patient first in a shared appointment and then provided a warm handoff to the psychiatrist. Visits were billed both by the physician and pharmacist according to International Classification of Diseases-10 and current procedural terminology codes. However, per VA operational policy, only the service with the highest amount billed was paid in cases in which multiple services were billed on the same day. Initially, the appointment time was divided equally between the pharmacist and psychiatrist but gradually transitioned to a pharmacist-led appointment with brief staffing with the psychiatrist at the end. A medical support assistant was responsible for ordering urine drug screens (UDS) and checking the state PDMP.

The pharmacist functioned under the scope outlined in the facility care-coordination agreement. Pharmacist responsibilities included review of UDS and PDMP results documented in the EHR, assessment of stability on current buprenorphine/naloxone treatment, naloxone prescribing and education, medication reconciliation, and assessment and management of comorbid MH conditions. The psychiatrist was responsible for reviewing information collected by the pharmacist during the patient appointment, collecting any additional information after staffing the case, and prescribing any medications as appropriate.

Descriptive data was collected over the course of the pilot, and matching data from a selected afternoon of psychiatrist-only appointments was collected over the same time course. Data collected included baseline demographic characteristics of patients, buprenorphine doses, UDS results, changes to concurrent MH medications, naloxone prescriptions, service referrals, adherence issues identified and addressed, and medication reconciliation interventions. Psychiatrist time saved through PPCPM appointments was calculated using an estimated 75% of time saved per appointment based on comparison of the average amount of time spent with patients in PPCPM versus non-PPCPM appointments.

Results

Twenty-five unique patients were seen in the PPCPM over a total of 44 appointments. An estimated 33 hours of psychiatrist time was saved using this model.
Table 1 summarizes baseline demographic characteristics of patients seen in the PPCPM and the matching group of patients seen in psychiatrist-only appointments. Overall baseline demographic and clinical characteristics were similar between groups. More patients in the PPCPM had a history of opioid-related overdose compared to psychiatrist-only appointments (24% vs 12%). Table 2 summarizes data regarding buprenorphine/naloxone treatment, UDS results, MH medication interventions, and other supportive services.

Average initial and end doses of buprenorphine were similar between patients seen in psychiatrist-only appointments and patients seen in the PPCPM (19.7 ± 9.8 mg and 19.6 ± 9.7 mg vs 20.6 ± 8.3 mg and 20.8 ± 7.1 mg, respectively). The number of buprenorphine/naloxone dose changes, number of changes to other MH medications, and number of new naloxone prescriptions were also similar between the 2 groups.

UDS were drawn in 89% of psychiatrist-only appointments compared to 98% of PPCPM appointments. Percentage of UDS positive for opioids and other illicit substances was similar between psychiatrist-only and PPCPM appointments. Buprenorphine was not detected in 16% of UDS from psychiatrist-only appointments compared to 9% of UDS in PPCPM appointments.

Forty-three percent of patients seen in the PPCPM were referred for outside services compared with 28% of patients seen in psychiatrist-only appointments (Table 2). These service referrals included tobacco-cessation treatment, metabolic syndrome clinic, primary care, specialty clinics, substance use support groups, psychotherapy, social work services, and whole health programs.

Sixty percent of patients seen in the PPCPM were identified to have MOUD adherence issues compared to 8% of patients seen in psychiatrist-only appointments (Table 2). Adherence issues were defined as taking either more or fewer daily doses of buprenorphine than prescribed. Every adherence issue was addressed in both the PPCPM and psychiatrist-only appointments. Adherence interventions included documentation of how a patient was taking buprenorphine/naloxone if taking differently than prescribed, provision of adherence counseling and interventions (eg, alarms, pill boxes), and instructions to change dose intervals of buprenorphine/naloxone as appropriate. Medication reconciliation was performed in every PPCPM appointment with provision of appropriate follow-up interventions (Table 2). Medication reconciliation interventions included discontinuation of

| Appointment Type | No. Patients | No. Appointments | Average Age, y | Male (%) | White (%) | History of Opioid-Related Overdose | MH Diagnosis (%)<sup>a</sup> | Concurrent MH Medications (%) |
|------------------|--------------|------------------|---------------|----------|-----------|-----------------------------------|-----------------------------|-----------------------------|
| Psychiatrist-only | 25           | 36               | 47            | 24 (96)  | 18 (72)  | 3 (12)                            | 23 (92)                    | 18 (72)                    |
| Physician-pharmacist collaborative practice model | 25           | 44               | 49            | 24 (96)  | 16 (64)  | 6 (24)                            | 24 (96)                    | 16 (64)                    |

MH = mental health.

<sup>a</sup>MH diagnosis includes anxiety, ADHD, bipolar disorder, depression, insomnia, PTSD, and schizophrenia.

| Appointment Type | Psychiatrist Only | PPCPM |
|-----------------|-------------------|-------|
| BUP treatment   |                   |       |
| Average initial dose (mg/d) | 19.7 (±9.8) | 20.6 (±8.3) |
| Average end dose (mg/d)   | 19.6 (±9.7) | 20.8 (±7.1) |
| Dosage range (mg/d)       | 1-32           | 6-32  |
| Dose changes (%)<sup>a</sup> | 4 (11)     | 4 (9)  |
| Urine drug screening results |          |       |
| Samples collected<sup>a</sup> | 32 (89)    | 43 (98) |
| (-) BUP<sup>b</sup> | 5 (16)       | 4 (9)  |
| (+) Opioid<sup>b</sup> | 3 (9)        | 3 (7)  |
| (+) Illicit substance (noncannabinoid, nonopioid)<sup>b</sup> | 3 (9)    | 3 (7)  |
| Other MH medication interventions |              |       |
| Changes to MH medications (%)<sup>a</sup> | 11 (31) | 11 (25) |
| Naloxone prescriptions (%)<sup>a</sup> | 5 (14) | 8 (18)  |
| Other supportive services |                |       |
| Service referrals (%)<sup>a</sup> | 10 (28) | 19 (43) |
| MOUD adherence issues addressed (%)<sup>a</sup> | 2 (8) | 15 (60) |
| Medication reconciliation interventions (%)<sup>a</sup> | 0 (0) | 21 (48) |

BUP = buprenorphine; MH = mental health.

<sup>a</sup>Per total number of patient appointments.

<sup>b</sup>Per total number of urine drug screens drawn.

<sup>c</sup>Per total number of patients.
medications patients were no longer taking, documentation of new medications in the EHR, and request for renewal of medications.

**Discussion**

Interventions regarding buprenorphine/naloxone treatment, UDS results, changes to MH medications, and naloxone prescribing were comparable between patients seen in the PPCPM and those seen in psychiatrist-only appointments. This supports using a PPCPM for provision of MOUD as it allows for a similar level of care with similar outcomes while saving psychiatrist time, thus enabling increased access to care.

Pharmacist involvement enhanced several aspects of patient care. In the PPCPM appointments, a larger percentage of patients was identified to be taking buprenorphine/naloxone differently than prescribed (60% vs 8%). This suggests that many adherence issues are either unidentified or undocumented in psychiatrist-only appointments. This is significant as MOUD nonadherence is associated with reduced retention in office-based outpatient treatment programs, increased drug diversion, and increased risk of relapse and overdose. In addition, UDS were ordered more frequently in PPCPM appointments compared with psychiatrist-only appointments, allowing for more consistent monitoring of adherence to treatment. The PPCPM allowed for close attention to MOUD adherence, which is vital in the effort to reduce risks associated with nonadherence.

Other unique interventions provided in PPCPM appointments included medication reconciliation interventions, which were not addressed in psychiatrist-only appointments. Referrals for other services were also higher in the PPCPM appointments. Pharmacist-led medication reviews in the outpatient setting have favorable outcomes regarding medication adherence, control of chronic disease states, appropriateness of medication, and medication/health care costs. The holistic approach of the PPCPM in regard to medication reconciliation and service referral is promising for improving health outcomes outside of the SUD specialty.

Results of this quality improvement initiative are subject to several limitations. All conclusions drawn from descriptive data rely on clinical inference. Direct causality to outcomes data cannot be drawn as the sample was not randomized. All data collected is subject to information bias as the accuracy of data was dependent on the documentation in the EHR. Findings have limited generalizability due to the small sample size, predominantly male and middle-aged Caucasian population, and single-center study design.

Barriers encountered included psychiatrist availability for planning, implementation and appropriate delineation of pharmacist versus psychiatrist roles regarding patient care, medication prescribing, documentation, and billing. Efforts to have regularly scheduled planning meetings prior to implementation and throughout the first weeks of the pilot to establish and review responsibilities would help address these barriers. Patients saw both the physician and pharmacist at each collaborative visit due to the need for development of trust between the psychiatrist and pharmacist and the short time frame of the pilot. However, this model shows promise for transitioning to independent pharmacist-led appointments, which would allow for patients to alternate between seeing the pharmacist and psychiatrist, thus expanding capacity of one individual X-waivered provider’s clinic capacity.

This pilot project lays the foundation for future initiatives of using pharmacists as physician-extenders for provision of MOUD. This model could be expanded into other areas, including general psychiatry, primary care, and emergency departments. Although provision of MOUD in the primary care setting offers easier access to treatment and decreased costs, availability is limited by lack of institutional support, lack of prescribing physicians, and lack of expertise. Emergency department–based buprenorphine induction programs are an effective method for maintaining patients on MOUD but are also underutilized. Pharmacist integration into primary care clinics and emergency departments through a PPCPM are potential avenues to address reported barriers and improve access to MOUD.

**Conclusion**

Implementation of a PPCPM allowed for provision of a similar level of care regarding MOUD and MH-related medication management while saving psychiatrist time. Other enhancements to patient care provided through pharmacist intervention included more frequent collection of UDS, identification and management of MOUD adherence issues, referral for other services, and medication reconciliation interventions.

**Acknowledgments**

This project is a result of collaboration with Dr Matthew Stohs and was supported with resources of the substance use disorder clinic at the Clement J. Zablocki Veterans Affairs Medical Center.

**References**

1. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States, 2019. Substance Use & Misuse. 2020;55(S1):133-178.
States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2016. Available from: https://www.samhsa.gov/data.
2. Wilson N, Karissa M, Seth P, Smith H IV, Davis NL. Drug and opioid-involved overdose deaths—United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020;69(21):290-7. DOI: 10.15585/mmwr.mm6921a4. Pubmed PMID: 32391688.
3. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. DOI: 10.1136/bmj.j1550. Pubmed PMID: 28446428. Pubmed PMID: 28446428.
4. Ma J, Bao Y-P, Wang R-J, Liu M-X, Li J-Q, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1868-83. DOI: 10.1038/s41386-018-0094-5. Pubmed PMID: 29934549.
5. Bukten A, Skurtveit S, Gossop M, Waal H, Stangeland P, Havnes I, et al. Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study. Addiction. 2012;107(2):393-9. DOI: 10.1111/j.1360-0443.2011.03677.x. Pubmed PMID: 21883606.
6. National Academies of Sciences, Engineering, and Medicine. Medications for opioid use disorder save lives. Washington: National Academies Press; 2019.
7. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63-75. DOI: 10.1097/HRP.0000000000000075. Pubmed PMID: 25747920.
8. Kakko J, Svanoord KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet. 2003;361(9358):662-8. DOI: 10.1016/S0140-6736(03)12600-1. Pubmed PMID: 12606177.
9. Butryn T, Bryant L, Marchionni C, Sholevar F. The shortage of psychiatrists and other mental health providers: causes, current state, and potential solutions. Int J Acad Med. 2017;3(1):5-9. DOI: 10.4203/JIAM.JIAM_49_17.
10. Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211-2. DOI: 10.1001/jama.2016.10542. Pubmed PMID: 27654608. Pubmed PMID: 27654608. Pubmed Central PMCID: PMC5257276.
11. Valenstein-Mah H, Hagedorn H, Kay CL, Christopher ML, Gordon AJ. Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the Veterans Health Administration. Subst Abus. 2018;39(3):284-8. DOI: 10.1080/08897077.2018.1509251. Pubmed PMID: 30325727.
12. Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1395-6. DOI: 10.1007/s11606-008-0688-x. Pubmed PMID: 18592319. Pubmed PMID: 18592319. Pubmed Central PMCID: PMC255806.
13. Gordon AJ, Kavanaigh G, Krumm M, Ramgopal R, Paiddetty S, Aghvai M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011;25(2):215-24. DOI: 10.1037/a0022776. Pubmed PMID: 21480679.
14. Dipaula BA, Menachery E. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients. J Am Pharm Assoc. 2003. 2015;55(2):187-92. DOI: 10.1332/japha.2015.14477. Pubmed PMID: 25749264.
15. Suzuki J, Matthews ML, Brick D, Nguyen M-T, Wasan AD, Jamison RN, et al. Implementation of a collaborative care management program with buprenorphine in primary care: a comparison between opioid-dependent patients and patients with chronic pain using opioids nonmedically. J Opioid Manag. 2014;10(3):159-68. DOI: 10.1055/s-0034-1389024. Pubmed PMID: 24940666. Pubmed PMID: 24940666. Pubmed Central PMCID: PMCID:408574.
16. Drug Addiction Treatment Act of 2000. The National Alliance of Advocates for Buprenorphine Treatment [updated 2016 Sep 20; cited 2020 Sep 20]. Available from: https://www.naabb.org/data2000.cfm
17. Centers for Medicare and Medicaid Services and National Center for Health Statistics [Internet]. ICD-10-CM official guidelines for coding and reporting [cited 2020 Sep]. Available from: https://www.cdc.gov/nchs/data/icd/icd10cmguidelines-FY2021.pdf
18. Current Procedural Terminology: Centers for Medicare & Medicaid Services [Internet]. Code list for certain designated health services [updated 2020 Feb 6; cited 2020 Dec 16]. Available from: https://www.cms.gov/Medicare/Fraud-and-Abuse/PhysicianSelfReferral/List_of_Codes
19. Warden D, Subramaniam GA, Carmody T, Woody GE, Minha-juddin A, Poole SA, et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addict Behav. 2012;37(9):1046-53. DOI: 10.1016/j.addbeh.2012.04.011. Pubmed PMID: 22626890.
20. Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003;98(5):673-84. DOI: 10.1046/j.1360-0443.2003.00354.x. Pubmed PMID: 12751985.
21. Tkacz J, Severt J, Cacciola J, Ruetsch C. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. Am J Addict. 2011;21(1):55-62. DOI: 10.1111/j.1521-0391.2010.00186.x. Pubmed PMID: 22211267.
22. Clausen T, Ancersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(3-4):153-7. DOI: 10.1016/j.drugalcdep.2007.11.003. Pubmed PMID: 18155364.
23. Schuman-Olivier Z, Borodovsky JT, Steinkamp J, Munir Q, Butler K, Greene MA, et al. MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study. Addict Sci Clin Pract. 2018;13(1):21. DOI: 10.1186/s13637-018-0122-4. Pubmed PMID: 30249779.
24. Jokanovic N, Tan EC, Sudhakaran S, Kirkpatrick CM, Dooley MJ, Sanchez DC, et al. Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program. Am J Emerg Med. 2020;38(2):300-4. DOI: 10.1016/j.ajem.2019.158373. Pubmed PMID: 31387831.